[go: up one dir, main page]

MX2023008159A - Anticuerpos neutralizantes para il-17a, proteinas de fusion de los mismos y usos de los mismos. - Google Patents

Anticuerpos neutralizantes para il-17a, proteinas de fusion de los mismos y usos de los mismos.

Info

Publication number
MX2023008159A
MX2023008159A MX2023008159A MX2023008159A MX2023008159A MX 2023008159 A MX2023008159 A MX 2023008159A MX 2023008159 A MX2023008159 A MX 2023008159A MX 2023008159 A MX2023008159 A MX 2023008159A MX 2023008159 A MX2023008159 A MX 2023008159A
Authority
MX
Mexico
Prior art keywords
fusion proteins
neutralizing antibodies
additionally provided
methods
compositions
Prior art date
Application number
MX2023008159A
Other languages
English (en)
Inventor
Daniel White
Crystal Lyles Jackson
Richard August Shimkets
Thomas Michael Vincent
Yonghua Luo
Original Assignee
Lanier Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lanier Biotherapeutics Inc filed Critical Lanier Biotherapeutics Inc
Publication of MX2023008159A publication Critical patent/MX2023008159A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se dan a conocer composiciones y métodos relacionados con anticuerpos anti-IL-17A, y fragmentos de unión a antígenos de los mismos. Adicionalmente, se proveen proteínas de unión biespecíficas que comprenden los dominios de unión anti-IL-17A. Adicionalmente, se proveen métodos de uso para los compuestos y composiciones, descritos en este documento, en el tratamiento de enfermedades inflamatorias y trastornos oculares.
MX2023008159A 2021-01-08 2022-01-10 Anticuerpos neutralizantes para il-17a, proteinas de fusion de los mismos y usos de los mismos. MX2023008159A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163135184P 2021-01-08 2021-01-08
PCT/US2022/011871 WO2022150728A1 (en) 2021-01-08 2022-01-10 Neutralizing antibodies to il-17a, fusion proteins thereof, and uses thereof

Publications (1)

Publication Number Publication Date
MX2023008159A true MX2023008159A (es) 2023-10-05

Family

ID=82357507

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008159A MX2023008159A (es) 2021-01-08 2022-01-10 Anticuerpos neutralizantes para il-17a, proteinas de fusion de los mismos y usos de los mismos.

Country Status (10)

Country Link
US (1) US20240301048A1 (es)
EP (1) EP4274848A4 (es)
JP (1) JP2024502608A (es)
KR (1) KR20230146011A (es)
CN (1) CN117083295A (es)
AU (1) AU2022205989A1 (es)
CA (1) CA3204572A1 (es)
IL (1) IL304116A (es)
MX (1) MX2023008159A (es)
WO (1) WO2022150728A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007026000A2 (en) * 2005-08-31 2007-03-08 Novo Nordisk Health Care Ag Human fvii monoclonal antibodies binding the gla domain and use thereof
WO2015014979A1 (en) * 2013-08-01 2015-02-05 F. Hoffmann-La Roche Ag Tnfa-il-17 bispecific antibodies
JP2020536967A (ja) * 2017-10-12 2020-12-17 イミュノウェイク インコーポレイテッド Ｖｅｇｆｒ−抗体軽鎖融合タンパク質
CN110386981A (zh) * 2018-04-20 2019-10-29 信达生物制药(苏州)有限公司 抗gitr抗体及其用途
PH12021551916A1 (en) * 2019-02-18 2022-05-23 Lilly Co Eli Therapeutic antibody formulation.

Also Published As

Publication number Publication date
US20240301048A1 (en) 2024-09-12
EP4274848A1 (en) 2023-11-15
CN117083295A (zh) 2023-11-17
WO2022150728A1 (en) 2022-07-14
IL304116A (en) 2023-09-01
JP2024502608A (ja) 2024-01-22
AU2022205989A1 (en) 2023-07-27
KR20230146011A (ko) 2023-10-18
AU2022205989A9 (en) 2024-09-19
EP4274848A4 (en) 2025-02-19
CA3204572A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
EP4566621A3 (en) Dll3/cd3 binding proteins for the treatment of cancer
EA200870274A1 (ru) ПЕПТИДЫ, БЛОКИРУЮЩИЕ СВЯЗЫВАНИЕ IgG C FcRn
NZ600584A (en) Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
MX343879B (es) Metodo de humanizacion de anticuerpo de conejo novedoso y anticuerpos de conejo humanizados.
PH12018550179A1 (en) Anti-pd-1 antibodies, method for producing same and method for using same
PH12021552334A1 (en) Antibodies to pyroglutamate amyloid-㟠and uses thereof
AR059604A1 (es) Anticuerpos contra il- 22 humana y usos para los mismos
MXPA06012601A (es) Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
EA201600276A1 (ru) Анти-il-17-антитела, способ их получения и способ применения
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
PE20212324A1 (es) Anticuerpos que reconocen tau
WO2022038417A3 (en) Modified il-18 polypeptides and uses thereof
MA39847A (fr) Protéines de liaison à l'antigène se liant à wisp1
ZA201907371B (en) Methods and compositions for treating allergic ocular diseases
NZ778810A (en) Antibodies targeting c5ar
WO2024191972A3 (en) Anti-lipocalin-2 antibodies and uses thereof
MX2025003153A (es) Anticuerpos anti-ccr8
MX2022012021A (es) Peptidos de dominios knob autonomos.
MX2023012300A (es) Anticuerpos humanos contra artemina y metodos de uso de estos.
MX2023013392A (es) Anticuerpos para tratar alfa-sinucleinopatias.
RU2380377C2 (ru) Nogo-A-СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ И ИХ ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
MX2023008159A (es) Anticuerpos neutralizantes para il-17a, proteinas de fusion de los mismos y usos de los mismos.
MX2025007872A (es) Anticuerpos anti-il-18bp
MX2021008453A (es) Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.